Global Biosimilar Market, By Product Type (Magnetic Resonance Imaging Scanners, Computed Tomography Scanners, Position Emission Tomography Scanners, Biosimilar (EEG), Electromyography Devices (EMG), Magnetoencphalography Devices, Transcranial Doppler Devices, Intracranial Pressure Monitors (ICP), Electrodes, Sensors, Gels and Cables), Drug Class (Insulin, Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor, Interferon, Erythropoietin, Etanercept, Monoclonal Antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, Enoxaparin Sodium), Type of Manufacturing (In-House Manufacturing and Contract Manufacturing), Procedure (Invasive and Non-Invasive), Disease (Stroke, Dementia and Epilepsy), Indication (Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Patent Foramen Ovale (PFO), Aortic Valve Stenosis and Others), Therapy Type (Oncology, Immunology, Haematology, Hormone Therapy, Metabolic Disorders, and Others), End Users (Hospitals, Clinics, Diagnostic Centres and Others) – Industry Trends and Forecast to 2030.
Biosimilar Market Analysis and Size
Rising number of research and development proficiencies have led to the rise in the availability of bio similar. Moreover, increased focus of food and drug administration on improving the penetration of Biosimilar is further helping the market to expand its roots.
Data Bridge Market Research analyses that the global biosimilar market which was USD 37,270.20 million in 2022, is expected to reach USD 343,520.90 million by 2030, and is expected to undergo a CAGR of 32.00% during the forecast period 2023-2030. “Oncology” dominates the product segment of the global biosimilar market owing to the owing to the increase in number of research studies, increasing research and development activities by key players focused on oncology and advancements in healthcare technologies. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Biosimilar Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Magnetic Resonance Imaging Scanners, Computed Tomography Scanners, Position Emission Tomography Scanners, Biosimilar (EEG), Electromyography Devices (EMG), Magnetoencphalography Devices, Transcranial Doppler Devices, Intracranial Pressure Monitors (ICP), Electrodes, Sensors, Gels and Cables), Drug Class (Insulin, Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor, Interferon, Erythropoietin, Etanercept, Monoclonal Antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, Enoxaparin Sodium), Type of Manufacturing (In-House Manufacturing and Contract Manufacturing), Procedure (Invasive and Non-Invasive), Disease (Stroke, Dementia and Epilepsy), Indication (Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Patent Foramen Ovale (PFO), Aortic Valve Stenosis and Others), Therapy Type (Oncology, Immunology, Haematology, Hormone Therapy, Metabolic Disorders, and Others), End Users (Hospitals, Clinics, Diagnostic Centres and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Orion Pharma AB (Sweden), Pfizer Inc. (U.S.), Samsung Bioepis. (South Korea), Coherus BioSciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company. (U.S.), Takeda Pharmaceutical Company Limited. (Japan), Bristol-Myers Squibb Company (U.S.), Merck KGaA (Germany), Teva Pharmaceutical Industries Ltd. (U.S.), Biocon. (India), Bayer AG (Germany), AbbVie Inc. (U.S.), Allergan (Ireland), Dr. Reddy’s Laboratories Ltd. (India), Boehringer Ingelheim International GmbH. (Germany) and Biogen (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Biosimilar or follow-on-biologics that are almost an identical copy of an original product but however, is manufactured by another company. Biosimilar is used to treat a wide range of chronic and acute diseases and disorders. Biosimilar is are used to record electrical action produced by the human brain.
Biosimilar Market Dynamics
Drivers
- The Rise in the Prevalence of Diseases
Surging prevalence of chronic and acute diseases all around the globe owing to various internal and external factors is one of the major factors responsible for fostering growth of the market. Rising patient pool especially in the developing economies coupled with growing cases of Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis is carving the way for the growth of the market.
- Research and Development Proficiencies
Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies have led to the advancements in the medical technology and have improved the quality of healthcare facilities. Increasing number of screening tests for research proficiencies has further widened the scope of growth.
- Government Investments on Healthcare Infrastructure
The increase in the funding by the federal government is set to drive the growth of the market. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative personal health devices market growth opportunities. Also, growing acceptance of bioidentical hormones replacement therapy by the governmental healthcare facilities is also bolstering the market growth rate.
Opportunity
- Rising Demand for Biologic Drugs
The increasing prevalence of chronic diseases and the growing aging population have led to a rise in the demand for biologic drugs. Biosimilar can help meet this demand and improve patient access to these essential treatments.
Restraint/Challenge
- Regulatory Hurdles
Developing and gaining regulatory approval for biosimilar involves complex and stringent regulatory pathways. Manufacturers need to demonstrate similarity to the reference biologic through comprehensive analytical and clinical studies, which can be time-consuming and costly.
This global biosimilar market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biosimilar market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In July 2020, the FDA approved the adalimumab biosimilar, Hulio, developed by Fujifilm Kyowa Kirin Biologics, which is indicated for the subcutaneous treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis
- In May 2020, Fresenius Kabi received the acceptance of the regulatory submissions for its proposed pegfilgrastim biosimilar (MSB11455) by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), respectively.
Global Biosimilar Market Scope
The global biosimilar market is segmented on the basis of product type, drug class, type of manufacturing, procedure, disease, indication, therapy type and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Magnetic Resonance Imaging Scanners
- Computed Tomography Scanners
- Position Emission Tomography Scanners
- Biosimilar (EEG)
- Electromyography Devices (EMG)
- Magnetoencphalography Devices
- Transcranial Doppler Devices
- Intracranial Pressure Monitors (ICP)
- Electrodes
- Sensors
- Gels
- Cables
Drug Class
- Insulin
- Recombinant Human Growth Hormone (RHGH)
- Granulocyte Colony-Stimulating Factor
- Interferon
- Erythropoietin
- Etanercept
- Monoclonal Antibodies
- Follitropin
- Glucagon
- Calcitonin
- Teriparatide
- Enoxaparin Sodium
Type of Manufacturing
-
In-House Manufacturing
- Contract Manufacturing
Procedure
-
Invasive
- Non-Invasive
Disease
-
Stroke
-
Dementia
- Epilepsy
Indication
-
Atrial Septal Defect (ASD)
-
Ventricular Septal Defect (VSD)
-
Patent Foramen Ovale (PFO)
- Aortic Valve Stenosis
- Others
Therapy Type
-
Oncology
- Immunology
- Haematology
- Hormone Therapy
- Metabolic Disorders
- Others
End Users
-
Hospitals
- Clinics
- Diagnostic Centres
- Others
Biosimilar Market Regional Analysis/Insights
The global biosimilar market is analysed and market size insights and trends are provided by country, product type, drug class, type of manufacturing, procedure, disease, indication, therapy type and end users as referenced above.
The countries covered in the global biosimilar market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global biosimilar market because of the strong base of healthcare facilities, availability of reimbursements, rising geriatric population, high healthcare spending combined with the onset of COVID-19 pandemic and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, ever-rising geriatric population base and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global biosimilar market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for Biosimilar market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Biosimilar market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Biosimilar Market Share Analysis
The global biosimilar market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global biosimilar market.
Some of the major players operating in the global biosimilar market are:
- Novartis AG (Switzerland)
- Orion Pharma AB (Sweden)
- Pfizer Inc. (U.S.)
- Samsung Bioepis. (South Korea)
- Coherus BioSciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Takeda Pharmaceutical Company Limited. (Japan)
- Bristol-Myers Squibb Company (U.S.)
- Merck KGaA (Germany)
- Teva Pharmaceutical Industries Ltd. (U.S.)
- Biocon. (India)
- Bayer AG (Germany)
- AbbVie Inc. (U.S.)
- Allergan (Ireland)
- Dr. Reddy’s Laboratories Ltd. (India)
- Boehringer Ingelheim International GmbH. (Germany)
- Biogen (U.S.)
SKU-